Stephens & Co. Reiterates Equal-Weight on Insight Molecular, Maintains $4 Price Target
Stephens & Co. analyst Mason Carrico reiterates Insight Molecular (NASDAQ:IMDX) with a Equal-Weight and maintains $4 price target.
Last updated: 2026-11-19 08:23:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Insight Molecular Diagnostics Inc. (IMDX) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $1.61, with a market capitalization of $58.31M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.50 to $7.51. This page covers its latest market performance, valuation, price trends and company information.
$58.31M | |
$1.75 | |
$2.00 | |
$1.51 | |
$1.78 | |
601.27K | |
245.02K | |
-- | |
$7.51 | |
$1.50 | |
-- | |
2026-06-30 |
Insight Molecular Diagnostics Inc. (IMDX) last closed at $1.61 as of 2026-11-18 23:52:00, down 12.36% ($0.22) from the previous close of $1.78.
During the latest regular trading session, IMDX traded between $1.51 and $2.00, with a volume of 601.27K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Insight Molecular Diagnostics Inc. (IMDX) moved from $2.47 to $1.61, representing a decline of 34.66% ($0.86).
The stock traded between $1.50 and $2.65 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 381.81 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.9%
IMDX is currently trading at $1.61, placing it 1.9% of the way from its 52-week low of $1.50 to its 52-week high of $7.51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 58 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Insight Molecular Diagnostics Inc. and IMDX stock.
Stephens & Co. analyst Mason Carrico reiterates Insight Molecular (NASDAQ:IMDX) with a Equal-Weight and maintains $4 price target.
Gainers Bullfrog AI Hldgs (NASDAQ:BFRG) stock moved upwards by 21.2% to $0.5 during Wednesday's pre-market session. The company's market cap stands at $7.6 million. As per the press release, Q3 earnings came
Gainers Aytu BioPharma (NASDAQ:AYTU) shares rose 45.0% to $2.64 during Tuesday's pre-market session. The market value of their outstanding shares is at $19.7 million. The company's, Q1 earnings came out
Eligible investors can buy real shares of Insight Molecular Diagnostics Inc. (IMDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to IMDX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between IMDX shares and USD.
IMDX Shares to USD
1.00 IMDX shares = 1.614 USD
Calculations are estimates based on the latest available price and are for reference only.